UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

PRM127 - The Futility of Cost-Efficacy Analysis

Value in health, 2015-11, Vol.18 (7), p.A705-A705

2015

Volltextzugriff (PDF)

The Futility of Cost-Efficacy Analysis

Value in health, 2015-11, Vol.18 (7), p.A705-A705

2015

Volltextzugriff (PDF)

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US : Analytic framework and review of the literature

PharmacoEconomics, 2005-01, Vol.23 (11), p.1107-1122

2005

Volltextzugriff (PDF)

Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease

Value in health, 2015-11, Vol.18 (7), p.A510-A510

2015

Volltextzugriff (PDF)

Vaccination against multiple HPV types

Mathematical biosciences, 2005-09, Vol.197 (1), p.88-117

2005

Volltextzugriff (PDF)

Formalizing Model Testing Methods: The Need For The Formation Of An Ispor Task Force On Model Testing Based On Software Engineering Best Testing Practices

Value in health, 2016-05, Vol.19 (3), p.A109-A109

2016

Volltextzugriff (PDF)

PRM215 - Formalizing Model Testing Methods: The Need For The Formation Of An Ispor Task Force On Model Testing Based On Software Engineering Best Testing Practices

Value in health, 2016-05, Vol.19 (3), p.A109-A109

2016

Volltextzugriff (PDF)

PUK14 - Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease

Value in health, 2015-11, Vol.18 (7), p.A510-A510

2015

Volltextzugriff (PDF)

Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach

Health economics, 2005-05, Vol.14 (5), p.457-470

Elbasha, Elamin H.

2005

Volltextzugriff (PDF)

Deadweight loss of bacterial resistance due to overtreatment

Health economics, 2003-02, Vol.12 (2), p.125-138

Elbasha, Elamin H.

2003

Volltextzugriff (PDF)

Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale

Health economics, 2004-01, Vol.13 (1), p.21-35

2004

Volltextzugriff (PDF)

PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL

Value in health, 2010, Vol.13 (7), p.A436-A436

2010

Volltextzugriff (PDF)

PIN52 AN ECONOMIC EVALUATION OF RALTEGRAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED PATIENTS IN HUNGARY

Value in health, 2010, Vol.13 (7), p.A439-A439

2010

Volltextzugriff (PDF)

Costs and benefits of a subtype-specific surveillance system for identifying Escherichia coli O157:H7 outbreaks

Emerging infectious diseases, 2000-05, Vol.6 (3), p.293-297

2000

Volltextzugriff (PDF)

Inequalities in self-reported physical health in the United States, 1993-1999

Health economics, 2005-04, Vol.14 (4), p.377-389

2005

Volltextzugriff (PDF)

Measuring the Economic Costs of Antimicrobial Resistance in Hospital Settings: Summary of the Centers for Disease Control and Prevention—Emory Workshop

Clinical infectious diseases, 2001-11, Vol.33 (9), p.1573-1578

2001

Volltextzugriff (PDF)

Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?

Health economics, 2003-03, Vol.12 (3), p.187-198

2003

Volltextzugriff (PDF)

PHP7 THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL: A GAME-THEORETIC ANALYSIS

Value in health, 2006-05, Vol.9 (3), p.A146-A146

2006

Volltextzugriff (PDF)

On Endogenous Growth: The Implications of Environmental Externalities

Journal of environmental economics and management, 1996-09, Vol.31 (2), p.240-268

1996

Volltextzugriff (PDF)

The calculation of research benefits with linear and nonlinear specifications of demand and supply: comment

American journal of agricultural economics, 1997-11, Vol.79 (4), p.1363-1367

Elbasha, Elamin H.

1997

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PRM127 - The Futility of Cost-Efficacy Analysis

The Futility of Cost-Efficacy Analysis

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US : Analytic framework and review of the literature

Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease

Vaccination against multiple HPV types

Formalizing Model Testing Methods: The Need For The Formation Of An Ispor Task Force On Model Testing Based On Software Engineering Best Testing Practices

PRM215 - Formalizing Model Testing Methods: The Need For The Formation Of An Ispor Task Force On Model Testing Based On Software Engineering Best Testing Practices

PUK14 - Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease

Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach

Deadweight loss of bacterial resistance due to overtreatment

Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale

PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL

PIN52 AN ECONOMIC EVALUATION OF RALTEGRAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED PATIENTS IN HUNGARY

Costs and benefits of a subtype-specific surveillance system for identifying Escherichia coli O157:H7 outbreaks

Inequalities in self-reported physical health in the United States, 1993-1999

Measuring the Economic Costs of Antimicrobial Resistance in Hospital Settings: Summary of the Centers for Disease Control and Prevention—Emory Workshop

Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?

PHP7 THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL: A GAME-THEORETIC ANALYSIS

On Endogenous Growth: The Implications of Environmental Externalities

The calculation of research benefits with linear and nonlinear specifications of demand and supply: comment

Suchergebnisse filtern